|Bid||72.4600 x 100|
|Ask||72.4800 x 300|
|Day's Range||71.8200 - 72.8400|
|52 Week Range||63.7600 - 86.2700|
|PE Ratio (TTM)||7.87|
|Forward Dividend & Yield||2.08 (2.87%)|
|1y Target Est||N/A|
Federal Reserve Chair Janet Yellen says she'll resign her seat on the Fed’s Board of Governors once Jerome Powell is confirmed and sworn in to replace her as head of the U.S. central bank. (VO) This is common for departing Fed chiefs to also leave the board at the same time as a courtesy to the new leader. What should investors expect as Trump stacks the central bank with his picks? Yahoo Finance's Alexis Christoforous and Jared Blikre discuss.
Stocks have managed to open roughly flat despite headwinds in Germany, where Angela Merkel’s coalition talks broke down overnight. What should investors be paying attention to as we head into this shortened holiday trading week? Yahoo Finance's Alexis Christoforous and Jared Blikre discuss.
In 3Q17, Merck’s (MRK) Zepatier generated revenue of $468 million, compared with $164 million in 3Q16. In 3Q17, Zepatier revenue fell 9% QoQ (quarter-over-quarter). During the first nine months of 2017,…...
After rising 15.4% in the first nine months of the year, the Medical-Biotech /Genetics industry has declined 13.4% so far in the fourth quarter.
Biotech behemoths like Celgene and Gilead struggled in the third quarter, leaving room for nimble innovators like Neurocrine, Exelixis and Juno Therapeutics to swipe headlines after crushing expectations.
To receive further updates on this Gilead Sciences, Inc. (NASDAQ:GILD) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of SlingShot Trader today.
Biotech and life sciences stocks have had a great run-up so far in 2017. Through the end of October, the S&P Biotechnology Select Sector Industry Index (SPSIBI) is up 52%. That makes the life science stocks some of best performers around. And what’s not to like?